ALX ONCOLOGY HOLDINGS INC Finance Lease, Right-of-Use Asset, after Accumulated Amortization
ALX ONCOLOGY HOLDINGS INC (ALXO) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $1.03 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.03M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.27M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.51M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.75M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $1.03M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.27M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $1.51M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.75M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $2.18M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $2.44M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $2.70M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $2.97M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $2.95M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $2.16M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $2.40M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $1.15M 10-Q · filed 2023-11-13 | |
| 2023-03-31 | $186.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $298.00K 10-K · filed 2024-03-07 | |
| 2022-09-30 | $410.00K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $522.00K 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $600.00K 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $746.00K 10-K · filed 2023-03-09 | $700.00K 10-K · filed 2022-02-28 |
| 2021-09-30 | $900.00K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.00M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $200.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |